Revenue
2022
2023
2024
2025
Adicet Bio, Inc. (ACET)
Price$9.56Cached quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $25.0M | — | — | — | — | — |
| Research & development | $99.1M | $99.3M | $106.0M | $71.2M | $48.9M | $34.3M | $23.7M | $14.7M | $16.8M |
| Operating expenses | $122.1M | $127.6M | $152.0M | $97.5M | $71.2M | $57.1M | $32.4M | $23.1M | $18.9M |
| Operating income | −$122.1M | −$127.6M | −$152.0M | −$72.6M | −$61.4M | −$39.2M | −$31.4M | −$15.0M | −$18.9M |
| Operating margin | — | — | — | −290.32% | — | — | — | — | — |
| EBITDA | −$115.7M | −$121.1M | −$145.9M | −$70.0M | −$59.9M | −$38.0M | −$30.1M | −$13.7M | −$18.9M |
| EBITDA margin | — | — | — | −280.02% | — | — | — | — | — |
| Net income | −$116.8M | −$117.1M | −$142.7M | −$69.8M | −$62.0M | −$36.7M | −$28.1M | −$9.3M | −$33.8M |
| Net profit margin | — | — | — | −279.27% | — | — | — | — | — |
| Basic EPSper basic share | -$16.95 | -$21.33 | -$52.96 | -$27.20 | -$32.00 | -$80.16 | -$210.40 | -$76.48 | -$1,086.45 |
| Diluted EPSper diluted share | -$16.95 | -$21.33 | -$52.96 | -$27.20 | -$32.00 | -$80.16 | -$210.40 | -$76.48 | -$1,086.45 |
Owners
Reported shareholders
9.96%of listed shares
RA CAPITAL MANAGEMENT, L.P.932.62K shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
RA CAPITAL MANAGEMENT, L.P. | 9.96%932.62K shares |
ORBIMED ADVISORS LLC | 9.02%844.79K shares |
FRANKLIN RESOURCES INC | 6.69%626.57K shares |
CITADEL ADVISORS LLC | 4.62%432.74K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.67%343.23K shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.93%274.38K shares |
RENAISSANCE TECHNOLOGIES LLC | 2.84%265.95K shares |
Stonepine Capital Management, LLC | 2.62%245.52K shares |
Alyeska Investment Group, L.P. | 2.18%203.8K shares |
Schonfeld Strategic Advisors LLC | 2.09%195.51K shares |
Carlyle Group Inc. | 1.97%184.3K shares |
NEXTBio Capital Management LP | 1.69%157.83K shares |
ACADIAN ASSET MANAGEMENT LLC | 1.33%124.83K shares |
Klickstein Lloyd | ≈1.16%108.57K shares |
TWO SIGMA INVESTMENTS, LP | 1.03%96.84K shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.02%95.63K shares |
DAFNA Capital Management LLC | 1.00%93.81K shares |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.92%85.96K shares |
MARSHALL WACE, LLP | 0.85%79.49K shares |
Trexquant Investment LP | 0.83%78K shares |
Percentages use 9.36M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 8, 2026Form 4 | OrbiMed Advisors Israel II Ltd +7TenPercentOwner | SellCommon Stock · indirect | 40.4K | $6.52 | $263.5K | 0 |
| Apr 8, 2026Form 4 | OrbiMed Advisors Israel II Ltd +7TenPercentOwner | SellCommon Stock · indirect | 32.5K | $6.29 | $204.6K | 0 |
| Apr 7, 2026Form 4 | OrbiMed Advisors Israel II Ltd +7TenPercentOwner | SellCommon Stock · indirect | 2.4K | $6.38 | $15.3K | 32.5K |
| Apr 7, 2026Form 4 | OrbiMed Advisors Israel II Ltd +7TenPercentOwner | SellCommon Stock · indirect | 29.3K | $6.53 | $191.5K | 34.9K |
| Feb 20, 2026Form 4 | RA Capital Healthcare Fund LP +3TenPercentOwner | BuyCommon Stock · indirect | 74.8K | $7.27 | $543.4K | 1.18M |
Community posts
Adicet reports lupus remissions and prepares pivotal study
Adicet Bio ($ACET) disclosed Phase 1 findings for its off-the-shelf CAR-T therapy prula-cel in systemic lupus erythematosus, with or without lupus nephritis. The efficacy dataset included 22 patients, with 13 followed for at least 12 months ...
